What Prinses Beatrix Spierfonds does

Prinses Beatrix Spierfonds is a Dutch charitable foundation (stichting) founded in 1956 during the polio epidemic, headquartered in Den Haag, the Netherlands. The foundation is the sole Dutch charity exclusively dedicated to funding scientific research into approximately 600 neuromuscular diseases, which collectively affect roughly 200,000 people in the Netherlands (1 in 9). Its mission is to stop, slow, or prevent progression of muscle diseases through funded research, with only a small minority of these diseases currently having an effective treatment. The foundation allocates roughly 60 ongoing research projects at any given time, approving 8-14 new projects per year, and operates core research programs in drug development, rehabilitation treatments, and clinical trial access for Dutch patients.

The foundation does not produce a commercial product or technology platform. Its 'products' are structured research programs (gene therapy, CAR-T cell therapy, Leefstijl op Maat lifestyle interventions), a quarterly donor magazine (Spierkrant), educational video series, and fundraising platforms (Spieractie, online collecting via QR codes). Research selection is governed by a rigorous independent peer-review process involving foreign experts, a Scientific Advisory Board, and a Patient User Commission. The foundation partners with Spierziekten Nederland (the Dutch patient association, subsidized since 1974), charity lotteries (Postcode Loterij and the Goede Doelen Loterijen coalition), and academic medical centers.

Its business model is multi-channel charitable fundraising: individual donations and periodic gifts (tax-deductible under ANBI status), the annual door-to-door collecte week with thousands of volunteers, sponsored sports events (marathons, Dam tot Damloop, Nijmeegse Vierdaagse, Egmond Halve Marathon), corporate partnerships, and legacies/bequests managed by a dedicated relatiemanager. Revenue is not publicly disclosed. The foundation is CBF-certified (Erkend Goed Doel) and ANBI-registered, with GDPR-compliant data practices.

Name

Prinses Beatrix Spierfonds

Legal name

Prinses Beatrix Spierfonds

Website

https://www.spierfonds.nl

Company type

Private

Founded year

1956

Operating status

Operating

Headcount range

11–50 employees

Short description

Prinses Beatrix Spierfonds is a Dutch charitable foundation, founded in 1956, that funds scientific research into all ~600 neuromuscular diseases affecting roughly 200,000 people in the Netherlands through donations, events, and charity lottery partnerships.

Ownership category

akta.pro rank

Product category

Charitable Medical Research Funding

NAICS

Voluntary Health Organizations (813212), Grantmaking Foundations (813211), Grantmaking and Giving Services (81321)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Health & Medical Research Grantmaking Foundations (BPAGAKAL), Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

• Muscle disease research
• Neuromuscular disease funding
• Charitable foundation
• Medical research grants
• Patient advocacy

Headquarters

HQ city

Den Haag

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Individual donations and gifts: One-time and recurring donations from individual donors, collected via website, SMS, direct bank transfer, and periodic giving agreements with tax benefit (ANBI). Core source of funding for research activities.
2. Door-to-door collecte (annual fundraising week): Annual door-to-door collection week (September) with thousands of volunteers canvassing neighborhoods. Also includes online digital collecting via personal QR-codes shared via WhatsApp and social media.
3. Legacies and bequests: Bequests and legacies left by supporters in their wills. Estate planning conversations facilitated by dedicated relatiemanager. An important and recurring revenue stream described as 'erg belangrijk' (very important).
4. Corporate partnerships and sponsorships: Corporate donations, sponsorships, salary donation programs, in-kind gifts, and benefit events. Companies can sponsor specific programs (e.g., Leefstijl op Maat) or act as strategic partners. Includes tax-deductible business gifts (ANBI status).
5. Lottery and charity partnerships: Structural funding from Goede Doelen Loterijen (charity lotteries), including Postcode Loterij contribution of €1 million. Partnerships with lottery organizations provide recurring structural support for research.
6. Sponsored events and action campaigns: Revenue from participant-driven events (marathons, Dam tot Damloop, Nijmeegse Vierdaagse, Fietselfstedentocht, Het Oranjepad) and personal action campaigns (e.g., cycling 2100km Santiago, rowing 3000km Gibraltar).

Go-to-market motion2 records

Distribution channels6 records

Marketing channels9 records

Core offering

Prinses Beatrix Spierfonds is a Dutch charitable foundation that funds scientific research into approximately 600 muscle diseases affecting roughly 200,000 people in the Netherlands. The foundation raises money through individual donations, an annual door-to-door collecte week, sponsored sporting events, legacies and bequests, corporate partnerships, and structural support from charity lotteries (including Postcode Loterij), and channels those funds into drug development research, rehabilitation treatment studies, clinical trial access, gene therapy and CAR-T cell therapy programs, talent development for researchers, and patient support in cooperation with Spierziekten Nederland.

Product overview

Prinses Beatrix Spierfonds is a Dutch charitable foundation focused on funding scientific research into muscle diseases (spierziekten). The organization operates as a unified research funding and patient support organization with multiple interconnected programs: core research programs in drug development and rehabilitation treatments; specialized programs including gene therapy, CAR-T cell therapy, and lifestyle interventions (Leefstijl op Maat); talent development initiatives for researchers; patient information and storytelling through the Spierkrant publication; and public engagement via events like Het Oranjepad and the Spieractie fundraising platform. The foundation does not offer a commercial tech product but rather funds research, provides patient support services, and raises awareness about muscle diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Onderzoek naar een medicijn (Medicine Research Program) Core research program funding scientific studies aimed at developing new or improved medicines to treat muscle diseases. Targets researchers at Dutch university medical centers.
• Onderzoek naar revalidatiebehandelingen (Rehabilitation Treatment Research) Research program focused on rehabilitation treatments that alleviate disease burden and measurably improve quality of life for muscle disease patients.
• Klinische trials naar Nederland (Clinical Trials to the Netherlands) Program to bring international clinical trials to Dutch patients, enabling participation in (inter)national clinical studies and accelerating access to effective therapies.
• Talentvolle onderzoekers (Talented Researchers Program) Program investing in the next generation of research leaders, including research chairs, talent symposia, and the Spierfonds Impact Award.
• Gentherapie voor spierziekten (Gene Therapy for Muscle Diseases) Gene therapy research program supporting multiple research lines since 2020, with the ambition to be ready for clinical trials in the Netherlands within years.
• CAR-T-celtherapie bij spierziekten (CAR-T Cell Therapy)

Quantifiable outcome

• Pompe disease treatment developed and brought to market — first-ever medicine for a muscle disease in history, saving lives of babies who previously did not survive their first year.
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Partnerships

Five partnerships are on record, tiered core, minor and flagship.

• Spierziekten NederlandcoreStrategic or Co-development Partner · 1 January 1974Spierziekten Nederland is the Dutch patient association for muscle diseases, supported by Spierfonds with an annual subsidy since 1974. The association advocates for people with muscle diseases, provides reliable information, and facilitates peer connections. The two organizations collaborate on events like the MD family day.
• NIBCminorGTM or Marketing PartnerNIBC wealth manager organized a charity art auction entirely dedicated to Spierfonds, raising over €6,600. The event combined an auction with educational content about muscle disease research.
• KP ActiveminorGTM or Marketing PartnerLifestyle brand KP Active organized 'Beyond Miles' event where the community covered 3,852.2 kilometers in 4 hours, with KP Active donating €1 per kilometer to Spierfonds.
• Egmond Halve MarathonflagshipGTM or Marketing PartnerSpierfonds is the official charity of the Egmond Halve Marathon 2027 (52nd edition, January 10, 2027). Over 18,500 runners participate. Both organizations will jointly raise funds for muscle disease research. This is a multi-year flagship partnership.
• Belastingdienst (Dutch Tax Authority)coreOthersThe foundation has ANBI (Algemeen Nut Beogende Instelling) status, meaning donations are tax-deductible for Dutch taxpayers. The Belastingdienst governs the regulatory framework that enables tax-efficient giving to Spierfonds.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Spierziekten Nederland: Dutch patient association for people with muscle diseases, funded by Spierfonds since 1974. Most directly comparable as the paired advocacy/community counterpart to Spierfonds' research-funding role, sharing the same patient community, governance standards, and Dutch health-charity regulatory environment.
• Stichting ALS Nederland: Dutch foundation funding research and patient support specifically for ALS. Operates the same ANBI-registered charity model with peer-reviewed research grants, sponsored events, and lottery partnerships — a directly comparable disease-specific Dutch research charity.
• Duchenne Parent Project: Dutch parent-led foundation funding Duchenne muscular dystrophy research and care. Highly comparable as a focused Dutch neuromuscular-disease research charity with similar fundraising channels, scientific advisory structure, and clinical-trial enablement goals.
• ReumaNederland: Dutch foundation funding rheumatology research and patient support. Comparable as a mid-sized ANBI/CBF-certified Dutch health research charity with peer-reviewed grants, sponsored events (Damloop, Marathon), lottery proceeds, and relatiemanager-driven major gift fundraising.
• Hartstichting: Dutch Heart Foundation, funding cardiovascular research and prevention. Closely comparable peer on fundraising mechanics: door-to-door collecte, Goede Doelen Loterijen proceeds, sponsored sports events, and ANBI/CBF certifications.

Broad incumbents

• Muscular Dystrophy Association (MDA): Large US-based muscle disease research and patient services organization. Comparable mission and program mix (research funding, clinical care, advocacy, summer camps) at significantly larger scale, serving as a benchmark for international neuromuscular-disease charity operations.
• KWF Kankerbestrijding: Largest Dutch health research charity (cancer). Operates a substantially scaled version of the same model — scientific peer review, sponsored events, lottery partnerships, ANBI status — and represents the benchmark for Dutch health-charity fundraising efficiency and scale.

Others

• ZonMw: Dutch organization for health research and care innovation, funding biomedical and translational research. Comparable as a health research grantmaking body using peer review, though state-funded rather than donation-funded; represents an institutional complement/co-funder for Spierfonds-supported research.
• NWO (Nederlandse Organisatie voor Wetenschappelijk Onderzoek): Dutch national science funding organization. Comparable as a large-scale scientific grantmaking body using independent peer review, often co-funding neuromuscular research projects alongside Spierfonds; relevant ecosystem peer for understanding Dutch research funding dynamics.
• EURORDIS (Rare Diseases Europe): European alliance of rare disease patient organizations. Comparable as an umbrella/advocacy body relevant to Spierfonds' rare neuromuscular disease portfolio, particularly for cross-border clinical trial access and EU rare-disease policy engagement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCxx
• Facebookfacebook.com/spierfonds
• LinkedInlinkedin.com/company/spierfonds
• Instagraminstagram.com/spierfonds

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prinses Beatrix Spierfonds